Adding value to Indigenous Knowledge through Scientific Innovation

Similar documents
Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development

Convention on Biological Diversity: ABS

Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery

Introduction to Drug Design and Discovery

PharmaMar A Biopharmaceutical Company

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Successful and Faster Drug Development through Data Mining Dirk Belmans, Ph.D. SAS Belgium

GUIDE HEA

International Expert to UNESCO in the field of Intangible Cultural Heritage

Supporting Scalable, Innovation Led, Enterprise.

395 South Youngs Road Buffalo, New York cognigencorp.com An On-Site 2-Day Workshop in Engineering The Pharmacometric Enterprise

THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS

1.The Task Force on Biomedicine and Health Innovation

UNLEASH THE POWER OF PRECISION MEDICINE

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Key Activities. Ofer Reizes, Ph.D. Skills Development Director

NIH-RAID: A ROADMAP Program

THE INNOVATION VALUE CHAIN: Stimulating and intensifying technological innovations in the South African Seed Industry

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Key Resources in Biomedical Product Development

Research and Innovation in Drug Discovery and Diagnostics

A drug development crossroad lies ahead

NATIONAL BIOPROSPECTING/BIOTRADE FORUM TERMS OF REFERENCE

MODEL-BASED DRUG DEVELOPMENT: A FDA CRITICAL PATH OPPORTUNITY

Regulatory Issues and Drug Product Approval for Biopharmaceuticals

Convention on Biological Diversity: ABS. Introduction to access and benefit-sharing

Malaria Research Capability Strengthening in Africa

A Machine-Learning Drug Design Platform Company BUSINESS OVERVIEW

The Commercial Use of Biodiversity: Access and Benefit Sharing in Practice.

Technology Transfer, Academic and Industry Cooperations

International Winter School Biodiversity, Ethnoecology and Bioprospecting in Nepal Himalaya Course details The main objective

INSTITUT PASTEUR INSTITUT PASTEUR IS A PRIVATE, NON PROFIT, INSTITUTE DEDICATED TO RESEARCH & PUBLIC HEALTH

REIMAGINING DRUG DEVELOPMENT:

= -1-EUROPEAN CD3. "Stimulating innovation in drug discovery" 21 May 2010 Innovation in Healthcare. Centre for Drug Design and Discovery

Career Growth Areas in Physiology / Pharmacology

Issues in Cancer Drug Development of the Future. Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007

What do we need to realize in silico medicine in the future?

The mystery of herbs The mastery of science

Establishment of Clinical Trial Infrastructure

FDA Driving Biomedical Product Innovation

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager

NEXT BIG WAVE IN PHARMACEUTICAL INDUSTRY

Technology Development Funding Program Round 3

CAAST-NET PLUS- RECs WORKSHOP PRETORIA, SOUTH AFRICA 4-5 FEBRUARY 2016 ANNELINE MORGAN SADC SECRETARIAT

Anti-cancer drug discovery: from bench to bedside

Paving the way to FDA? tips and pitfalls. The Nextar start up support program Dr. Orna Dreazen- CEO

Compound Re-Profiling. Dr Robert Scoffin CEO, Cresset

Life Sciences Debashis Ghosh. 1 Copyright 2016 Tata Consultancy Services Limited

Drug Repositioning. Cresset European User Group Meeting 21 st June 2012

Overview of Biotechnology in Thailand

Job Title: Head, Clinical Science Job Location: Nanjing, China CV to: Wechat:

CONVERGENCE IN ENABLING TECHNOLOGIES FOR GREEN GROWTH

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program

The High Level Dialogue: Towards Transforming Agricultural Research for Development Globally

PIONEERING WORLD-CLASS DRUG DISCOVERY IN AFRICA

Panama City, Panama April, 12-15, Marcelo Mario Matos Moreira. The Brazilian Health Surveillance Agency (ANVISA)

BIOSTATISTICAL METHODS

novel drug molecule for the treatment of Chronic Pain

Biomarker Utility and Acceptance in Drug Development and Clinical Trials: an FDA Regulatory Perspective

Global Environment Facility (GEF) and Nagoya Protocol Implementation Fund (NPIF) Supported Access and Benefit Sharing (ABS) Projects

BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH

Some challenges in the development of new toxicity assays using in vitro methods

Frequently Asked Questions

Webinar IMI2 - Call 17 Opportunities for SMEs

To the Department of Trade and Industry (the dti) 11 October Background. For Attention: Ms Meshendri Padayachy,

Cellular Assays. A Strategic Market Analysis. Sample Slides

APPLICATION OF TRADITIONAL KNOWLEDGE IN THE FOREST MANAGEMENT: ETHNOBOTANICAL INDICATORS FOR SUSTAINABLE USE OF FOREST

Engage with us on Twitter: #Molecule2Miracle

ABPI response to European Commission consultation on advanced therapy medicinal products

DMTC Technology Readiness Levels Guideline

IMI: A Public Private Partnership Funder

Sustainable Agriculture Research for International Development

The Future of Pharmaceutical Quality

Sowa Rigpa Drug Research its scope and Challenges

Micar Innovation. Drug Discovery Factory for novel drug molecules

ECO-PHARMACO- STEWARDSHIP (EPS) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT OF PHARMACEUTICALS IN THE ENVIRONMENT (ipie)

PHARMACEUTICALS AND INTELLECTUAL PROPERTY TRAINING SEMINAR. Medicines: from discovery to patient

Benefit-Sharing & Biotrade. Gus Le Breton

Centre for Drug Design and Discovery CD3. Centre for Drug Design and Discovery

Developing AI Technology Platform in Hospital Authority

SMEs in IMI2 Calls for Proposals

The Food and Drug Administration Predictive Toxicology Roadmap and its Implementation

University of California Center for Accelerated Innovation

Integrated Agricultural Systems for the Poor and Vulnerable

Oncology Product and Platform Partnering Opportunity

Preclinical studies needed in the development of human pharmaceutical drugs role of toxicology and risk assessment

COPYRIGHTED MATERIAL QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS. Rohin Mhatre and Anurag S. Rathore 1.1 INTRODUCTION

Government s role in developing solutions for diseases that disproportionately affect developing countries

Financial Results FY2018 Q3

Novartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program

Many traditional farmers provide environmental

Tsumura to Hold Presentation on Vision for Business in China

MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT

Challenges in Antimicrobial Clinical Development. Axel Dalhoff & Heino Staß Institut für Klinische Pharmakologie Bayer AG, Wuppertal, D

Horticulture for Sustainable Development and Global Food Security

Bioengineering to reduce animal use and improve drug development

Digital Health A PRAGMATIC REGULATORY APPROACH

Policies that encourage innovation in middle-income countries

FDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development. October 4, 2004

The current options to control infectious diseases in livestock and the stimulation of innovation to develop new treatments

Transcription:

THE WORLD BANK Adding value to Indigenous Knowledge through Scientific Innovation INTERNATIONAL WORKSHOP ON INDIGENOUS KNOWLEDGE Benoni, South Africa 9-11 February 2005 Marthinus Horak Programme CSIR Bio/Chemtek Pretoria

IKS definition (World Bank) Local knowledge Unique to every culture or society Basis for local-level decision making in : Agriculture, health care, food preparation, education, natural resource management, etc. Provides problem solving strategies for communities Community rather than individual knowledge Tacit knowledge, difficult to codify, embedded in community practices, etc.

IKS some thoughts IKS is different, but equal, to Western knowledge systems IKS may have ancient origins, but is relevant in day-to-day lives of people Continues to evolve Is highly validated in context of community/local use

IKS in context of Global Development Millenium Development Goals: Eradicate poverty and hunger, improve education, gender equality, health issues, environmental sustainability and partnerships for development IKS can contribute significantly to development Must be leveraged with other knowledge resources Value addition to IKS through scientific innovation can create new benefits for society Requires partnerships

What is? The search for valuable chemical and genetic constituents of biodiversity

Vision for Add maximum value to bio-resources and indigenous knowledge through consortium-based research, thereby creating economic and social benefit for all stakeholders

strategy Biodiversity Scientific Innovation Indigenous Knowledge

S A s plant biodiversity 19 500 indigenous plant species 8% of all plant species on earth 60% endemicity Mainly unexplored as source of natural medicines 25% of world s pharmaceuticals are derived from plants

Indigenous Knowledge 200 000 Traditional Healers in SA >70% of population regularly consult a Healer Possibly 3 000-5 000 plants may have biological activity

CSIR signs agreement with Traditional Healers (1999)

Drug Development Cycle Discovery Development: Phase I, II, III and regulatory approval Commercial Sales Cumulative Investment Lead Discovery Early Proof Of Concept CSIR Time Multinational companies

Classic, rational approach to drug discovery Therapeutic concept Efficacy Assay (HTS) Screen compounds Evolve SAR and MC concepts Preclinical Development compound In vivo Pharmacodynamics In vitro models n-th NCE First NCE, iterate patent analytical production Pharmaco kinetics Toxicology IND Clinical Development compound New drug launch NDA submission Phase 3 Clinical study Phase 2 Clinical study Phase 1 Clinical study

in partnership with Traditional Healers Therapeutic concept Efficacy Assay (HTS) Screen compounds Evolve SAR and MC concepts Preclinical Development compound In vivo Pharmacodynamics In vitro models n-th NCE First NCE, iterate patent analytical production Pharmaco kinetics Toxicology IND Clinical Development compound New drug launch NDA submission Phase 3 Clinical study Phase 2 Clinical study Phase 1 Clinical study

CSIR facilities High-throughput plant collection and extraction Data and information management Nuclear magnetic resonance, mass spectrometry, high-pressure liquid chromatography, gas chromatography Plant biotechnology including tissue culture laboratories Clinical Supplies Unit, Botanical Supplies unit Good Farming Practice, Good Manufacturing Practice, Good Laboratory Practice

Consortium-based research: key component of No research group, company, country or region can control full value chain in CSIR Consortium consists of: Traditional Healers Universities Research institutes Communities Micro-enterprises

CSIR partners

Knowledge management challenges in The needle is hidden in a very big haystack Nearly 250 000 plant species 50 years of modern research data Centuries of experiential learning of Traditional Healers Data and information security Communication between representatives of different knowledge systems Stimulate scientific innovation Support quality assurance procedures e.g. Good Laboratory Practice

Artificial Intelligence Artificial neural networks may be constructed to assist recognition of patterns such as ecosystem-speciesbiological activity relationships Aimed at implementation in southern African region, based on experimental data from South African species

Protection of intellectual assets: what are intellectual assets? Intellectual Capital Intellectual Assets intangible: learning, experience, capability to innovate People based information, technology, Indigenous Knowledge Product/technology based Intellectual Property Unique and highly valuable product or technology

Creation and protection of intellectual assets Intellectual Capital Search, record and add value Intellectual Assets Innovate Intellectual Property (IP) Involve owners of knowledge as partners in Keep secret Trademark/brand Develop into IP Patent

Commercialization of products Creation and licensing of patented Intellectual property Very long development periods Difficulty typically underestimated Rewards can be very high Production and sale of biodiversity products e.g. self-medication products (not patented) Regulatory environment is complex Requires strong brand identity

Risk vs. Return in High Patented drug leads Profit potential Low Herbal products Low Degree of value added High

Anti-obesity agent from Hoodia

Hoodia in its natural habitat

Hoodia: cultivation site

Anti-obesity agent (P57): structure elucidation

Community involvement Establishment of community-owned businesses, based on agro-processing Focus on alternative crops e.g. aromatic and medicinal plants Technology transfer and skills development allow value-adding processing Communities become partners in commercialization of bioprospecting successes

Current activities Signed benefit-sharing agreements with owners of Indigenous Knowledge (San Council and Traditional Healer Trust) Signed bioprospecting agreement with Namibia (2005) Collected one-third of SA plant biodiversity (>8 000 plant species) Investigating more than 400 ethnobotanical leads provided by Traditional Healers

IKS-led drug leads under development Asthma and allergies Inflammation Arthritis Benign prostatic hyperplasia HIV Wound healing Malaria

THE WORLD BANK Challenges for this IKS Workshop Establish framework for collaboration: World Bank, GRA and Traditional Healers Identify pilot projects aimed at validation of IK Develop roadmap for the partnership, aimed at implementation of IK in support of sustainable development Present outcomes at 4 th Annual Meeting of GRA Principals and future World Bank Conference

THE WORLD BANK Thank you for your attention